ZIA BC 011344 (ZIA) | |||
---|---|---|---|
Title | Immune suppressor mechanisms in patients with GI cancer | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Greten, Tim | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $51,497 | Project Dates | 00/00/0000 - 00/00/0000 |
Fiscal Year | 2017 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Digestive Diseases (100.0%) |
Colon/Rectum (10.0%) Liver Cancer (65.0%) Pancreas (25.0%) |
||
Research Type | |||
Vaccines Systemic Therapies - Discovery and Development |
|||
Abstract | |||
ne of the major problems in immune therapy is that we do not understand why some treatments work and others fail in patients. We use samples from patients treated with anti-CTLA4 plius locoregional therapy to better understand how immune based approaches work in HCC. We are studying tumor samples from patients on our studies using gene expression analysis and perform flowcytometry studies on PBMC. These studies are ongoing. So far we have been able to demonstrate that patients with tumor infiltrating T cells are more likely to respond to anti-CTLA4 plus locoregional therapy |